Black Seed for Blood Sugar
Black seed (Nigella sativa) — also called black cumin or kalonji — has quietly accumulated more human trial evidence for glycemic control than most of the herbs above it in reputation. The trials are small and the preparations are not standardised, but there are a lot of them and they point the same way.
Evidence tier 2, at the strong end. Consistent pooled effects from many small studies of modest quality.
Table of Contents
What the Pooled Evidence Shows
Karimi and colleagues' 2025 systematic review and meta-analysis in Complementary Therapies in Medicine pooled 16 randomised controlled trials in type 2 diabetes and found black seed supplementation significantly reduced:
- Fasting blood glucose by 21.43 mg/dL (P = 0.005)
- Hemoglobin A1c (HbA1c) by 0.44 percentage points (P = 0.01)
- Total cholesterol by 18.80 mg/dL (P = 0.04), with low-density lipoprotein (LDL) also reduced, by 19.53 mg/dL (P = 0.003)
The same analysis found no significant effect on 2-hour after-meal glucose, fasting insulin, the HOMA score (homeostatic model assessment, a measure of insulin resistance), triglycerides, HDL cholesterol, the liver enzymes AST and ALT, creatinine (a kidney marker), body weight or body mass index (BMI).
An earlier 2022 pooled analysis by Saadati and colleagues in Frontiers in Nutrition, covering 11 randomised trials in people with prediabetes or type 2 diabetes, found improvements in fasting glucose, HbA1c, total and LDL cholesterol, C-reactive protein (a marker of inflammation) and malondialdehyde (a marker of oxidative damage), with no overall change in glucose after a glucose-tolerance test, fasting insulin, HOMA-IR (insulin-resistance score), triglycerides, HDL cholesterol or BMI. In its subgroups, HOMA-IR fell in trials longer than 8 weeks, and BMI fell in trials using more than 1 g a day.
Separately, Jafari and colleagues published a GRADE-assessed systematic review and dose-response meta-analysis in Pharmacological Research in 2025 covering 82 studies and 5,026 participants, with doses ranging from 200 to 4,600 mg/day over 1 to 48 weeks — a genuinely large body of work by herbal-supplement standards.
A hemoglobin A1c reduction of 0.44 points is not trivial; it is in the range some pharmaceutical add-ons achieve. The caveats are the familiar ones and they are real: individual trials are small, blinding is variable, much of the work comes from a small number of research environments, and — the practical problem — "black seed" covers whole seed, ground seed, fixed oil and thymoquinone-standardised extracts, which are not interchangeable.
Thymoquinone
Thymoquinone is the principal active constituent and the one most preparations are standardised against when they are standardised at all. The proposed actions are the usual cluster — improved insulin sensitivity, protection of pancreatic beta cells from oxidative stress, reduced hepatic gluconeogenesis — supported mainly by preclinical work. In people, the 16-trial analysis above found no significant change in fasting insulin or in the HOMA insulin-resistance score.
The non-standardisation is the crux for anyone buying it. A trial using a thymoquinone-standardised oil and a jar of ground kalonji from a grocery are not the same intervention, and the meta-analytic average is computed across both.
Dosing
Trial doses span 200 mg to 4,600 mg a day — a twenty-threefold range, which is itself a statement about how unsettled the dosing is. The commonly used practical range is around 1–3 g/day of ground seed, or 1–2 g/day of the oil, taken with food.
The 2025 analysis of 16 trials in type 2 diabetes looked at dose and duration in its subgroups: fasting glucose fell in trials lasting longer than 8 weeks, while HbA1c, the HOMA score and LDL cholesterol fell at doses above 1 g a day, in shorter trials (8 weeks or less) and with the oil form.
Because the preparations differ so much, results from one black seed product do not carry over to another; glucose readings show what a given product does for a given person.
Cautions
- It lowers blood glucose, and so do diabetes medicines. The effects add. With insulin or a sulfonylurea, the combined effect can push blood sugar too low (hypoglycemia: shaking, sweating, confusion) — the signs are listed on hypoglycemia awareness and prevention.
- Possible effects on drug metabolism. Thymoquinone has shown activity on the cytochrome P450 (CYP) liver enzymes that break down many medicines in preclinical (laboratory and animal) work; this matters most for narrow-therapeutic-index medicines, where a small change in blood level makes a large difference.
- Pregnancy. Animal studies report effects on the uterus; there are no human safety data for therapeutic doses in pregnancy.
- Glucose readings show interactions early. When a supplement is added without measuring, an interaction shows up as a symptom rather than as a number.
- Kidney case report. A 2013 case report in the Journal of Integrative Medicine describes acute kidney failure (acute renal failure) associated with Nigella sativa in a patient with diabetes.
Key Research Papers
Every DOI below was checked against Crossref and the abstract read for support before it was listed.
- Karimi, et al. Effects of black seed (Nigella sativa L.) on cardiometabolic indices in type 2 diabetic patients: a systematic review and meta-analysis of RCTs. Complementary Therapies in Medicine, 2025;90:103174 — doi:10.1016/j.ctim.2025.103174 — Sixteen randomised trials.
- Jafari, et al. Does Nigella sativa supplementation improve cardiovascular disease risk factors? A comprehensive GRADE-assessed systematic review and dose-response meta-analysis of 82 randomized controlled trials. Pharmacological Research, 2025;219:107882 — doi:10.1016/j.phrs.2025.107882 — Eighty-two studies, 5,026 participants.
- Saadati S, Naseri K, Asbaghi O, Abhari K, Zhang P, Li HB, Gan RY. Nigella sativa supplementation improves cardiometabolic indicators in population with prediabetes and type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Nutrition, 2022;9:977756 — PubMed PMID: 36034891
- Arslan E, Sayin S, Demirbas S, Cakar M, Somak NG, Yesilkaya S, Saglam K. A case study report of acute renal failure associated with Nigella sativa in a diabetic patient. Journal of Integrative Medicine, 2013;11(1):64-66 — PubMed PMID: 23464648